Fiercebiotech.com

Click on 'Go to the website!' to go to Fiercebiotech.com.

Button get active in 5

Other newsletters from Fiercebiotech.com

Reveal Hidden Tumor Complexity with Single-Cell Genomic Profiling
Fiercebiotech.com
1752522623
Is Your Viral Safety Strategy Ready for the Next Regulatory Shift?
Fiercebiotech.com
1752522571
| 07.14.25 | BD, Waters' $17.5B deal creates lab to ol powerhouse; FDA rejects Ultragenyx’s gene therapy
Fiercebiotech.com
1752519857
The First Barrier Isn’t the Last—It’ s Just the Start of the Domino Effect
Fiercebiotech.com
1752516327
E, save your spot for this upcoming webinar?
Fiercebiotech.com
1752513917
| 07.14.25 | AZ's $1.3B CinCor bet scores in hypertension ph. 3; FDA denies Ultragenyx AAV gene therapy
Fiercebiotech.com
1752507802
Don't be the only one at Your Company who misses this webinar - Register now
Fiercebiotech.com
1752335317
| 07.12.25 | Trump signs 'big, beautiful bill'; Judge hits CVS' Omnicare with $949M in penalties
Fiercebiotech.com
1752323568
| 07.11.25 | FDA document drop sheds light on drug refusal process; Agency rejects Capricor DMD cell therapy
Fiercebiotech.com
1752255796
Why top gene therapy manufacturers are rethinking lysis
Fiercebiotech.com
1752254803
| 07.11.25 | FDA rebuffs Capricor’s DMD cell thera py; Karyopharm shrinks workforce as pressure mounts
Fiercebiotech.com
1752250330
| 07.11.25 | Biopharma layoffs jump 32% in first half of 2025; Trump renews 200% tariff threat on drugs
Fiercebiotech.com
1752239503
Biologics Are Booming—Is Your Delivery Strategy Keeping Up?
Fiercebiotech.com
1752175175
| 07.10.25 | FDA publishes 200 drug rejection letters; After 16 years, Jazz has a new CEO
Fiercebiotech.com
1752174532
The Chemistry Breakthrough You've Been Waiting For
Fiercebiotech.com
1752170981
| 07.10.25 | FDA shares 200-plus drug rejection letters; AbbVie pays $700M for J&J, Pfizer blood cancer rival
Fiercebiotech.com
1752163866
Key Factors That Impact CDMO Success in Rare Disease Programs
Fiercebiotech.com
1752089102
| 07.09.25 | Merck makes $10B respiratory M&A p lay for Verona; AZ’s Alexion pens $825M AAV pact
Fiercebiotech.com
1752088137
| 07.09.25 | AZ’s Alexion inks $825M AAV pact ; Rhythm obesity pill hits high note in ph. 2
Fiercebiotech.com
1752078573
| 07.08.25 | H1 biopharma layoffs up 32% YOY; Novartis' malaria drug for infants wins world-first approval
Fiercebiotech.com
1752004205